Rankings
▼
Calendar
TGTX Q3 2019 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$38,000
+0.0% YoY
Gross Profit
$38,000
100.0% margin
Operating Income
-$61M
-160160.5% margin
Net Income
-$62M
-162973.7% margin
EPS (Diluted)
$-0.69
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$33M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$93M
Total Liabilities
$119M
Stockholders' Equity
-$662M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$38,000
$38,000
+0.0%
Gross Profit
$38,000
$38,000
+0.0%
Operating Income
-$61M
-$34M
-77.3%
Net Income
-$62M
-$34M
-82.4%
← FY 2019
All Quarters
Q4 2019 →